| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| γ-Linolenic acid (GLA) — an omega-6 polyunsaturated fatty acid (18:3 n-6) found in high concentration in borage oil, evening primrose oil, and blackcurrant seed oil. Metabolized to dihomo-γ-linolenic acid (DGLA) → precursor of anti-inflammatory eicosanoids (e.g., PGE1). Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Orally absorbed and incorporated into membrane phospholipids; rapidly elongated to DGLA. Plasma levels achievable with supplementation; cellular effects reflect incorporation over days–weeks (remodeling). In-vitro vs oral exposure: Direct tumor cytotoxicity generally observed at supra-physiologic concentrations; physiologic doses mainly alter lipid signaling rather than induce apoptosis. Clinical evidence status: Used for inflammatory conditions (e.g., dermatitis, RA); oncology data limited and inconsistent; no cancer approval. GLA (abundant in borage oil) has shown anti-proliferative and pro-apoptotic effects on multiple cancer cell lines and in animal models (mechanisms include ER stress, mitochondrial dysfunction, altered eicosanoid signaling).-Borage plants can contain unsaturated PAs(Pyrrolizidine alkaloids) which are hepatotoxic and genotoxic/carcinogenic. Many authorities advise only using borage oil products certified PA-free, and caution against long-term or high-dose use. -γ-gamma linolenic acid (GLA, 18:3n-6) are polyunsaturated fatty acids (PUFA) that improve the human health γ-Linolenic Acid (Borage Oil) — Cancer vs Normal Cell Pathway Map
TSF legend: |
| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 4509- | GLA, | Gamma-linolenic Acid (GLA) sensitizes pancreatic cancer cells to gemcitabine |
| - | in-vitro, | PC, | PANC1 |
| 4510- | GLA, | Gamma-linolenic acid therapy of human glioma-a review of in vitro, in vivo, and clinical studies |
| - | Review, | NA, | NA |
| 4513- | GLA, | Antineoplastic Effects of Gamma Linolenic Acid on Hepatocellular Carcinoma Cell Lines |
| - | in-vitro, | Liver, | HUH7 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:374 Target#:1110 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid